Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LA1 peptide
- Development stage
- Preclinical
- Lead developer
- Johns Hopkins University
- Modality
- Peptides
01
Overview
LA1 peptide (also known as La1) is a synthetic 12-amino acid cyclic peptide identified via phage display library screening that specifically binds to the surface of *Leishmania amazonensis* metacyclic promastigotes (MPs). Developed by researchers at São Paulo State University (UNESP) in collaboration with Johns Hopkins University and Mercer University, the peptide is designed to inhibit the interaction and internalization of *L. amazonensis* parasites into host phagocytic cells, such as THP-1 macrophages. By blocking parasite entry, LA1 peptide serves as a species-specific candidate for the prevention and early intervention of cutaneous leishmaniasis at the sand fly bite site, or as a tool to identify parasite ligands for vaccine development.
- Other names
- L. amazonensis binding peptide (La1)La1 peptideLa-1 peptideLa 1 peptide
Beyond the preview
Go deeper on LA1 peptide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LA1 peptide.